Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Natural Order Acquisition Corp. Announces Closing of $230 Million Initial Public Offering, which Includes Full Exercise of the Underwriters' Over-Allotment Option
-
Immunovant (IMVT) PT Raised to $60 at Chardan Capital Markets
-
Natural Order Acquisition Corp. (NOAC) Prices 20M Unit IPO at $10/Unit
-
Natural Order Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
-
Form 10-Q Chardan Healthcare Acqui For: Sep 30
-
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Mallard Acquisition Corp. Announces Closing of $110 Million Initial Public Offering
-
Forte Biosciences (FBRX) Announces Pricing of $40 Million Public Offering of Common Stock at $28.50/sh
-
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
-
Forte Biosciences (FBRX) Announces Proposed Public Offering of Common Stock
-
Forte Biosciences Announces Proposed Public Offering of Common Stock
-
Mallard Acquisition Corp. Announces Pricing of $110 Million Initial Public Offering
-
Chardan Capital Markets Starts Axcella Health Inc. (AXLA) at Buy, $16 PT; 'Simplified Approach to Improving Metabolic Health'
-
UPDATE: Chardan Capital Markets Starts Immunome Inc. (IMNM) at Buy, Bullish on Antibody Discovery Platform
-
Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement
-
Gensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional Investors
-
Chardan Capital Markets Starts Taysha Gene Therapies (TSHA) at Buy
-
Hudson Capital Inc. Enters into Definitive Merger Agreement with FreightHub, Inc., a North American Digital Transportation Logistics Platform Company with a Focus on US-Mexico Cross-Border Shipping
-
Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $50 at Chardan Capital Markets on Delay
-
Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
-
Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
-
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
CARISMA Therapeutics to Participate in Upcoming Investor Conferences
-
OncoMyx to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
-
Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
-
Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th
-
Immunome (IMNM) IPO Opens 31% Higher
-
Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference
-
Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference
-
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference
-
Immunome Inc. (IMNM) Prices 3.25M Share Upsized IPO at $12/Sh
-
Immunome Announces Pricing of Upsized Initial Public Offering
-
Solid Biosciences (SLDB) PT Raised to $12.50 at Chardan Capital Markets
-
LogicBio Therapeutics (LOGC) Prices 7M Share Public Offering of Common Stock at $6/Each
-
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
-
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
-
Mustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020
-
Mustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020
-
Editas Medicine to Participate in Upcoming Investor Conference
-
Editas Medicine to Participate in Upcoming Investor Conference
-
Diginex Lists and Begins Trading on Nasdaq
-
Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference
-
Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference
-
Sensorion Announces Attendance and Presentations at Upcoming Conferences
-
LogicBio Therapeutics (LOGC) Announces Proposed Common Offering
-
LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
-
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
-
LogicBio Therapeutics Announces Proposed Public Offering of Common Stock

